- Home
- Publications
- Publication Search
- Publication Details
Title
Old and New Biological Therapies for Psoriasis
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 11, Pages 2297
Publisher
MDPI AG
Online
2017-11-02
DOI
10.3390/ijms18112297
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
- (2017) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
- (2017) A. Menter et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Richard B Warren et al. LANCET
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis
- (2016) K.F. Hjuler et al. BRITISH JOURNAL OF DERMATOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study
- (2016) Hidemi Nakagawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
- (2016) Hidehisa Saeki et al. JOURNAL OF DERMATOLOGY
- Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis
- (2016) Róbert Kui et al. JOURNAL OF DERMATOLOGY
- 346 IL-17F regulates psoriasis-associated genes through IκBζ
- (2016) T. Bertelsen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
- (2016) L. Cai et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology
- (2016) E. Daudén et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-12 protects from psoriasiform skin inflammation
- (2016) Paulina Kulig et al. Nature Communications
- Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis
- (2016) April W. Armstrong et al. JAMA Dermatology
- Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis
- (2015) Kasper Fjellhaugen Hjuler et al. AMERICAN JOURNAL OF MEDICINE
- Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- (2015) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Small Molecules in the Treatment of Psoriasis
- (2015) Tiago Torres et al. DRUG DEVELOPMENT RESEARCH
- The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents
- (2015) Tulin Ergun et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Infliximab-Related Infusion Reactions: Systematic Review
- (2015) Lev Lichtenstein et al. Journal of Crohns & Colitis
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2015) Richard B. Warren et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab treatment shows no evidence for reactivation of previous or latent TB infection in subjects with psoriasis: A pooled phase 3 safety analysis
- (2015) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC
- (2015) A. Nast et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on psoriasis immunopathogenesis and targeted immunotherapy
- (2015) Satveer K. Mahil et al. Seminars in Immunopathology
- ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
- (2014) J.M.P.A. van den Reek et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
- (2014) R. Gniadecki et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- PASI90 response: the new standard in therapeutic efficacy for psoriasis
- (2014) L. Puig JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
- (2014) H. Saeki et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost Effectiveness of Biologic Therapies for Plaque Psoriasis
- (2013) Christine S. Ahn et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response
- (2013) Leeyen Hsu et al. Expert Review of Clinical Immunology
- Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis
- (2013) Bruce W. Kirkham et al. IMMUNOLOGY
- Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation
- (2013) A. Johnston et al. JOURNAL OF IMMUNOLOGY
- Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions
- (2013) J. Spertino et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Biosimilars: what clinicians should know
- (2012) M. Weise et al. BLOOD
- The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
- (2012) David A. Martin et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
- (2012) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment
- (2012) T.C. Lucka et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
- (2011) Yihua Cai et al. IMMUNITY
- Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
- (2011) Tsen-Fang Tsai et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan
- (2011) Tsen-Fang Tsai et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
- (2011) Atsuyuki IGARASHI et al. JOURNAL OF DERMATOLOGY
- Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
- (2011) Kenneth B. Gordon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
- (2011) Kenneth Gordon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
- (2011) A. Puel et al. SCIENCE
- Involvement of IL-17F via the induction of IL-6 in psoriasis
- (2010) Sawa Fujishima et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.
- (2010) K Abuabara et al. BRITISH JOURNAL OF DERMATOLOGY
- A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study
- (2010) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- How tumour necrosis factor blockers interfere with tuberculosis immunity
- (2010) J. Harris et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial
- (2010) Hideshi Torii et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
- (2010) Akihiko ASAHINA et al. JOURNAL OF DERMATOLOGY
- Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris
- (2010) A. Clemmensen et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing Long-Term Drug Safety: Lessons (Re) Learned from Raptiva
- (2010) Nicole M. Seminara et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
- (2009) C. Johansen et al. BRITISH JOURNAL OF DERMATOLOGY
- Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
- (2009) N. N. Mehta et al. EUROPEAN HEART JOURNAL
- Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis
- (2009) Heather R. Conti et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines
- (2009) Consuelo Ortega et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis
- (2008) C. Leonardi et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
- (2008) J. Schmitt et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials
- (2008) A.K. Brimhall et al. BRITISH JOURNAL OF DERMATOLOGY
- Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety
- (2008) Michael P. Schön CLINICS IN DERMATOLOGY
- Functional Characterization of IL-17F as a Selective Neutrophil Attractant in Psoriasis
- (2008) Hideaki Watanabe et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started